Acadia, Neurocrine See Stock Price Bump After Quarterly Earnings

We?re in the midst of earnings season, and a couple of San Diego?s publicly traded biotechs recently updated investors this week with sales data and other financial insights. Here?s a look at those companies. ?Acadia Pharmaceuticals faced a setback in July with the failure of a late-stage trial that was testing pimavanserin?which the company?s sells [?]